Bio-Path Holdings Inc(NASDAQ:BPTH) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.01.
Bio-Path Holdings Inc (BPTH) shares turned negative on Fridays trading session with the shares closing down -0.0328 points or -4.09% at a volume of 3,35,290. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.8949. The peak price level was also seen at $0.8949 while the days lowest was $0.74. Finally the shares closed at $0.77. The 52-week high of the shares is $3.19 while the 52-week low is $0.7005. According to the latest information available, the market cap of the company is $74 M.
Several Insider Transactions has been reported to the SEC. On Jul 15, 2015, Michael J. Garrison (director) purchased 7,343 shares at $1.22 per share price.
Bio-Path Holdings Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer drugs under a license arrangement. The Company’s lead cancer drug candidate Liposomal Grb-2 (L-Grb-2 or BP1001) is undergoing clinical trials. The Company’s two liposomal antisense drug candidates are focused to treat acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) chronic myelogenous leukemia (CML) acute lymphoblastic leukemia (ALL) and follicular lymphoma. BP1001 is its lead liposome delivered antisense drug candidate which has been clinically tested in patients having AML CML MDS and ALL. BP-100-1.02 (Bcl-2 or BP1002) is its second liposome delivered antisense drug candidate. Clinical targets for BP1002 include lymphoma breast cancer colon cancer prostate cancer and leukemia. The Company has a drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense.